CEO Gavin MacBeath was paid $2,801,450 in fiscal year 2025 (SEC filing 0001193125-26-160304 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,801,450 Gavin MacBeath total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
TCRX's next annual pay disclosure, estimated March 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gavin MacBeath | $665,000 | $0 | $0 | $1,982,800 | $139,650 | $0 | $14,000 | $2,801,450 |
| Chief Executive Officer and Director | ||||||||
| Chrystal Louis | 530,000 | 0 | 0 | 991,400 | 74,200 | 0 | 14,000 | 1,609,600 |
| Chief Medical Officer | ||||||||
| Jason Amello | 520,000 | 0 | 0 | 669,195 | 72,800 | 0 | 14,000 | 1,275,995 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gavin MacBeath | $2,801,450 | $1,760,671 | — | ↑ +1,040,779 |
| Chrystal Louis | 1,609,600 | 3,030,461 | — | ↓ −1,420,861 |
| Jason Amello | 1,275,995 | 3,733,892 | — | ↓ −2,457,897 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read TScan Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TCRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the TScan Therapeutics, Inc. Peer Teardown Report
$2,801,450 Gavin MacBeath total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 2, 2026 · Source: 0001193125-26-160304 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for TCRX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order TCRX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name TCRX as a peer is temporarily unavailable — recheck shortly.
Get the TScan Therapeutics, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Barbara Klencke, M.D | Independent Director | $145,779 |
| Gabriela Gruia, M.D | Independent Director | $129,122 |
| Garry Nicholson | Independent Director | $125,363 |
| Katina Dorton, J.D., M.B.A | Independent Director | $139,109 |
| R. Keith Woods | Independent Director | $125,265 |
| Stephen Biggar, M.D., Ph.D | Chair of the Board | $162,232 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| R. Keith Woods | Director | 2026-05-20 | A | 67,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Gabriela Gruia | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barbara Klencke | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katina Dorton | Director | 2026-05-20 | A | 67,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gavin MacBeath | Director | 2026-10-01 | A | 1,000,000 | 0 | 0 | Common | Form 4 ↗ |
| Zoran Zdraveski | See Remarks | 2026-10-01 | A | 300,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chrystal Louis | OPTION | 2025-01-03 | — | — | 400,000 | — | $994,825 |
| Gavin MacBeath | OPTION | 2025-01-03 | — | — | 800,000 | — | 1,989,651 |
| Jason Amello | OPTION | 2025-01-03 | — | — | 270,000 | — | 671,507 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chrystal Louis | $0 | $0 | $994,825 | 0.0% |
| Gavin MacBeath | 0 | 0 | 1,989,651 | 0.0% |
| Jason Amello | 0 | 0 | 671,507 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gavin MacBeath | Option | 11,667 | 1.81 | — |
| Gavin MacBeath | Option | 83,334 | 6 | — |
| Jason Amello | Option | 390,625 | 5.15 | — |
| Gavin MacBeath | Option | 14,584 | 3.27 | — |
| Gavin MacBeath | Option | 316,875 | 2.49 | — |
| Chrystal Louis | Option | 400,000 | 3.07 | — |
| Jason Amello | Option | 270,000 | 3.07 | — |
| Gavin MacBeath | Option | 189,940 | 2.49 | — |
| Gavin MacBeath | Option | 2,917 | 4.85 | — |
| Chrystal Louis | Option | 221,667 | 8.62 | — |
| Gavin MacBeath | Option | 800,000 | 3.07 | — |
TScan's compensation program is designed to attract and retain highly qualified named executive officers by providing competitive base salaries, performance-based annual cash incentive bonuses tied to corporate and individual goals, and long-term equity incentives in the form of stock options to align executive interests with stockholder value creation. The company does not generally provide perquisites or personal benefits beyond standard health and welfare plans available to all employees.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | — | — | — | — | — |
| 2025 | 2025-06-30 | — | — | — | — | — |
| 2024 | 2024-06-12 | — | — | — | — | — |
| 2023 | 2023-06-13 | — | — | — | — | — |
| 2022 | 2022-06-01 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-20 | —a |
| 2025 | 2025-06-30 | —b |
| 2024 | 2024-06-12 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen Biggar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Research and Clinical Development | $90,609 | $0 | $71,623 | $0 | $0 | $162,232 |
| Barbara Klencke, M.DIndependent · Audit · Compensation · Research and Clinical Development (Chair) | 74,156 | 0 | 71,623 | 0 | 0 | 145,779 |
| Katina Dorton, J.D., M.B.AIndependent · Audit (Chair) · Compensation · Nominating/Governance | 67,486 | 0 | 71,623 | 0 | 0 | 139,109 |
| Gabriela Gruia, M.DIndependent · Audit · Nominating/Governance · Research and Clinical Development | 57,499 | 0 | 71,623 | 0 | 0 | 129,122 |
| Garry NicholsonIndependent · Nominating/Governance (Chair) · Research and Clinical Development | 53,740 | 0 | 71,623 | 0 | 0 | 125,363 |
| R. Keith WoodsIndependent · Audit · Compensation | 53,642 | 0 | 71,623 | 0 | 0 | 125,265 |
| Gavin MacBeath, Ph.DEmployee director · Research and Clinical Development | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $71,623 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $397,132 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $397,132 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TScan Therapeutics, Inc. | 2025 | Gavin MacBeath | $665,000 | $0 | $1,982,800 | $139,650 | $2,801,450 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gavin MacBeath | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387 |
| 2 | Section 01, Chrystal Louis | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 1,609,600. Filing ↗machine: t40 · r6 · c27 · span 229201–229210 |
| 3 | Section 01, Jason Amello | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Summary Compensation Table”. As printed: 1,275,995. Filing ↗machine: r4 · c27 · span 224738–224747 |
| 4 | Section 03, Chrystal Louis OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 5 | Section 03, Gavin MacBeath OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 6 | Section 03, Jason Amello OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 7 | Section 07, pay ratio | 10-K | 2026-03-04 | 0001193125-26-089884 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Stephen Biggar, M.D., Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 162,232. Filing ↗machine: t54 · r2 · c11 · span 304325–304332 |
| 9 | Section 08, Barbara Klencke, M.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 145,779. Filing ↗machine: t54 · r5 · c11 · span 307586–307593 |
| 10 | Section 08, Katina Dorton, J.D., M.B.A | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 139,109. Filing ↗machine: t54 · r3 · c11 · span 305408–305415 |
| 11 | Section 08, Gabriela Gruia, M.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 129,122. Filing ↗machine: t54 · r4 · c11 · span 306509–306516 |
| 12 | Section 08, Garry Nicholson | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 125,363. Filing ↗machine: t54 · r7 · c11 · span 309752–309759 |
| 13 | Section 08, R. Keith Woods | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 125,265. Filing ↗machine: t54 · r6 · c11 · span 308681–308688 |
| 14 | Section 08, Gavin MacBeath, Ph.D | DEF 14A | 2026-04-17 | 0001193125-26-160304 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, R. Keith Woods 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236855 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Gabriela Gruia 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236848 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Garry Nicholson 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236854 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, BAKER BROS. ADVISORS LP 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236870 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, BAKER BROS. ADVISORS LP 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236870 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Barbara Klencke 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236841 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Katina Dorton 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-236844 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Gavin MacBeath 2026-10-01 | Form 4 | 2026-10-02 | 0001193125-26-412521 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Zoran Zdraveski 2026-10-01 | Form 4 | 2026-10-02 | 0001193125-26-412518 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 06, 2026 vote | Form 8-K | 2026-05-22 | 0001193125-26-236862 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 25 | Section 06, 2025 vote | Form 8-K | 2025-07-02 | 0001193125-25-154336 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 26 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001193125-24-161151 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 27 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 28 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 29 | Section 09b board cost (computed) | Computed | — | — | Cash 397,132 + equity 0 + all other 0 = 397,132, summed across the director compensation table rows.machine: formula: Σ = 397,132 |
| 30 | TScan Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160304 | CEO total compensation as printed in TScan Therapeutics, Inc.'s own proxy. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the TScan Therapeutics, Inc. Executive Compensation Report
$1,500